

# Harmony™

## PRENATAL TEST


An advanced blood test to assess the risk of fetal trisomies and evaluate the X and Y chromosomes

### A simple, safe blood test

- \* Highly accurate, individualized results for you, your practice and patients<sup>1-6</sup>
- \* Performed anytime after 10 weeks' gestation
- \* Lowest cumulative false positive rate<sup>1-6</sup>

# Advanced Technology Behind the Harmony Test

## The Advantages of Directed Analysis



- ▶ Cell-free DNA are short DNA fragments from chromosomes found in circulation
- ▶ In pregnancy, cell-free DNA from the fetus and mother are both present in maternal blood<sup>3</sup>
- ▶ The Harmony test uses efficient, directed analysis for accurate trisomy detection


## Informative Results

- ▶ Easy interpretation: Simple “High-Risk” or “Low-Risk” reporting for each trisomy
- ▶ Personalized risk results incorporate chromosome counts, fetal DNA fraction, gestational age, and maternal age
- ▶ 99.5% of risk score values are at either risk cutoff (<1/10,000 or >99%) for autosomal trisomies
- ▶ X and Y Analysis with the Harmony Prenatal Test offers >99% accuracy for fetal sex<sup>7</sup>

### Test Results

Fetal cfDNA Percentage: 10.5%


CHROMOSOME	RESULT	PROBABILITY	RECOMMENDATION
Trisomy 21 (T21)	HIGH RISK	Greater than 99/100 (99%)	Genetic counseling and additional testing
Trisomy 18 (T18)	Low Risk	Less than 1/10,000 (0.01%)	Review results with patient
Trisomy 13 (T13)	Low Risk	Less than 1/10,000 (0.01%)	Review results with patient
Y Analysis	Male Fetus	Greater than 99/100 (99%)	Review results with patient



### Fetal fraction – key determinant for results

- ▶ A minimum amount of fetal cfDNA is necessary for reliable testing and quality results
- ▶ The Harmony test incorporates the measurement of fetal cfDNA into the analysis of **every sample**
- ▶ Increased maternal weight and early gestational age may contribute to the presence of low fetal cfDNA (<4%)<sup>7</sup>

### Effect of maternal weight as it correlates to ≥4% fetal cfDNA (%)



# Accurate:

Enhanced Performance with Individualized Results<sup>1-7</sup>

Studied in over  
6,000 patients,  
including >2,000  
average-risk  
women<sup>1-7</sup>

T21

T18

T13

## Test Performance

## False Positive Rate

>99% (231 of 232)	<0.1%
>98% (103 of 105)	<0.1%
8 of 10	<0.1%



**X and Y analysis** is >99% accurate for fetal sex. It can also assess risk for sex chromosome conditions with test performance varying by the type of condition detected.<sup>7</sup>

- Only non-invasive prenatal test (NIPT) that has been exclusively evaluated in 1st trimester pregnant women
- Results in 99% of your patients with proper sample collection
- 95% of results reported within 9 days of accessioning<sup>7</sup>

## Clinical Utility in a General Screening Population<sup>6</sup>

Nicolaides K.H., Syngelaki A., Ashoor G, et al., Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. *Am J Obstet Gynecol* (2012); 207:374.e1-6.

Harmony<sup>TM</sup>  
PRENATAL TEST



■ Trisomy    ◆ False Positive    ◆ Non-Trisomy


- Both figures have the same number of patients
- 10 cases of trisomy 21 or trisomy 18
- 1,939 non-trisomy cases

## Flexible for Multiple Patient Populations

- ▶ The Harmony Prenatal Test detects >99% of fetal trisomy 21 cases at a false positive rate of <0.1%
- ▶ Optional X and Y chromosome analysis available for fetal sex and X,Y sex chromosome analysis
- ▶ This test does not assess risk for mosaicism, partial trisomies or translocations
- ▶ The Harmony test is available for all singleton and twin pregnancies, including those conceived by IVF



### Performance of Screening Tests for Trisomy 21<sup>4,7</sup>



The Harmony Prenatal Test has been developed and is performed as a laboratory test service by Ariosa Diagnostics, a CLIA-certified clinical laboratory located in California, USA.

Ariosa®, Harmony™, and Harmony Prenatal Test™ are trademarks of Ariosa Diagnostics, Inc.  
 ©2013 Ariosa Diagnostics, Inc. All rights reserved.  
 Customer service: 1-855-9-ARIOSA (855-927-4672)

1. Sparks, A.B., Struble, C.A., Wang, E.T., Song, K., Oliphant, A., Non-invasive Prenatal Detection and Selective Analysis of Cell-free DNA Obtained from Maternal Blood: Evaluation for Trisomy 21 and Trisomy 18, *Am J Obstet Gynecol* (2012), doi: 10.1016/j.ajog.2012.01.030.
2. Ashoor, G., Syngelaki, A., Wagner, M., Birdir, C., Nicolaides, K.H., Chromosome-selective sequencing of maternal plasma cell-free DNA for first trimester detection of trisomy 21 and trisomy 18, *Am J Obstet Gynecol* (2012), doi: 10.1016/j.ajog.2012.01.029.
3. Sparks, A.B., Wang, E.T., Struble, C.A., Barrett, W., et al., Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. *Prenat Diagn* (2012); 32(1):3-9. doi: 10.1002/pd.2922. Epub 2012 Jan 6.
4. Norton, M., Brar, H., Weiss, J., Karimi, A., et al., Non-Invasive Chromosomal Evaluation (NICE) Study: Results of a Multicenter, Prospective, Cohort Study for Detection of Fetal Trisomy 21 and Trisomy 18, *Am J Obstet Gynecol* (2012), doi:10.1016/j.ajog.2012.05.021.
5. Ashoor, G., Syngelaki, A., Nicolaides, K.H., et al., Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method, *ULTRASOUND Obstet Gynecol* (2012), DOI: 10.1002/uog.12299.
6. Nicolaides K.H., Syngelaki A., Ashoor G, et al., Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. *Am J Obstet Gynecol* (2012); 207:374.e1-6.
7. Internal data on file.